C57BL/6J

Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress

Retrieved on: 
Friday, October 6, 2023
Congress, Central nervous system, C57BL/6J, Therapy, CORAL, European College of Neuropsychopharmacology, Psilocybin, CNS, Data, ECNP, CEST, Pharmaceutical industry

CORAL GABLES, Fla., Oct. 6, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will present three posters at the upcoming 36th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 7-10, 2023, in Barcelona, Spain.

Key Points: 
  • CORAL GABLES, Fla., Oct. 6, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will present three posters at the upcoming 36th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 7-10, 2023, in Barcelona, Spain.
  • Details of the poster presentations are as follows:
    Date & Time of Presentations: Sunday, October 8, 2023, 12:35-2:00pm CEST
    Poster Title: Behavioral effects of a 14-day repeated treatment with psilocybin at a low non-psychedelic dose: a preliminary study in C57BL/6J mice
    The posters will be available in the Data and Publications section of the Relmada website following the conclusion of the event.
  • For additional information about ECNP 2023, click here .

Iterion Therapeutics Announces Results from Preclinical Study of Tegavivint in Beta-Catenin Mutant Hepatocellular Carcinoma to be Presented at the 34th EORTC-NCI-AACR Symposium 2022

Retrieved on: 
Tuesday, October 18, 2022
CET, Therapy, Population, Acute myeloid leukemia, AML, Squamous cell carcinoma, ENA, Neoplasm, Patient, American Association for Cancer Research, Molecule, Hepatocellular carcinoma, Research, HCC, Sarcoma, Metastasis, Cancer Prevention and Research Institute of Texas, C57BL/6J, GEMM, Research institute, SCI, Treatment, Mouse, National Cancer Institute, AACR, NSCLC, European Organisation for Research and Treatment of Cancer, Cancer research, American Association, Toxicity, CEO, EORTC, Transducin, Cancer prevention, Osteosarcoma, Lymphoma, Literature, Homeostasis, Death, Cell membrane, NCI, Large-cell lung carcinoma, Pharmaceutical industry, Medical imaging, Cancer

HOUSTON, Oct. 18, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, announced that results from a preclinical murine study of tegavivint in beta-catenin activated hepatocellular carcinoma (HCC) will be featured in a poster presentation and discussion session at the 34th European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI), and American Association for Cancer Research (AACR) Symposium (ENA 2022). ENA 2022 is being held October 26-28, 2022, in Barcelona, Spain.

Key Points: 
  • Increased expression of beta-catenin and TBL1 are associated with metastasis and poor prognosis in a broad range of tumor types, including HCC.
  • Up to 50% of HCC patients have tumors driven by activating beta-catenin and canonical Wnt pathway mutations.
  • Additionally, in mice with established tumors, tegavivint treatment increased CD3+ T-lymphocyte tumor infiltration, with prominent increases in intratumoral CD8+ T-cells.
  • Iterion is currently advancing multiple clinical programs investigating tegavivint in cancer indications where nuclear beta-catenin overexpression is a known factor.